|
1
|
Ablinger M, Lettner T, Friedl N, Potocki H, Palmetzhofer T, Koller U, Illmer J, Liemberger B, Hainzl S, Klausegger A, Reisenberger M, Lambert J, Van Gele M, Desmet E, Van Maelsaeke E, Wimmer M, Zauner R, Bauer JW, Wally V. Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa. Int J Mol Sci 2021; 22:3326. [PMID: 33805154 PMCID: PMC8036626 DOI: 10.3390/ijms22073326] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 03/17/2021] [Accepted: 03/20/2021] [Indexed: 02/06/2023] Open
Abstract
Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders therapy developments challenging. However, the high number of short in-frame exons facilitates the use of antisense oligonucleotides (AON) to restore collagen 17 (C17) expression by inducing exon skipping. In a personalized approach, we designed and tested three AONs in combination with a cationic liposomal carrier for their ability to induce skipping of COL17A1 exon 7 in 2D culture and in 3D skin equivalents. We show that AON-induced exon skipping excludes the targeted exon from pre-mRNA processing, which restores the reading frame, leading to the expression of a slightly truncated protein. Furthermore, the expression and correct deposition of C17 at the dermal-epidermal junction indicates its functionality. Thus, we assume AON-mediated exon skipping to be a promising tool for the treatment of junctional epidermolysis bullosa, particularly applicable in a personalized manner for rare genotypes.
Collapse
Affiliation(s)
- Michael Ablinger
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Thomas Lettner
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Nicole Friedl
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Hannah Potocki
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Theresa Palmetzhofer
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Ulrich Koller
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Julia Illmer
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Bernadette Liemberger
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Stefan Hainzl
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Alfred Klausegger
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Manuela Reisenberger
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
- Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria
| | - Jo Lambert
- Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium; (J.L.); (M.V.G.); (E.D.); (E.V.M.)
| | - Mireille Van Gele
- Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium; (J.L.); (M.V.G.); (E.D.); (E.V.M.)
| | - Eline Desmet
- Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium; (J.L.); (M.V.G.); (E.D.); (E.V.M.)
| | - Els Van Maelsaeke
- Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium; (J.L.); (M.V.G.); (E.D.); (E.V.M.)
| | - Monika Wimmer
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Roland Zauner
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| | - Johann W. Bauer
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
- Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria
| | - Verena Wally
- Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; (M.A.); (T.L.); (N.F.); (H.P.); (T.P.); (U.K.); (J.I.); (B.L.); (S.H.); (A.K.); (M.R.); (M.W.); (R.Z.); (J.W.B.)
| |
Collapse
|
|
3
|
Lorenz B, Wörle J, Friedl N, Hasenfratz G. Ocular growth in infant aphakia. Bilateral versus unilateral congenital cataracts. Ophthalmic Paediatr Genet 1993; 14:177-88. [PMID: 8015788 DOI: 10.3109/13816819309042916] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In a prospective study the changes in the ocular axial lengths and in the overall refractions were examined in cases of unilateral and bilateral congenital cataract requiring surgery during the first year of life. Measurements were taken on 18 children with unilateral and on 20 children with bilateral congenital cataract at the time of surgery and up to eight years postoperatively. Surgery was performed via a pars plana/plicata approach, and all infants were fitted with contact lenses. In cases of unilateral cataract, the ocular axial length tended to be superior to the age-matched values already prior to surgery. After four to eight years, one third of the eyes were clearly above normal. In cases of bilateral cataract, the axial lengths were reduced at the age of surgery in the majority of cases, and particularly in eyes that required surgery during the first six months of life. The curvatures of the contact lenses tended to remain unchanged in bilateral cataract, and decreased by about 0.7 mm in unilateral cases. This also reflects the high degree of microphthalmia in bilateral cases. After four to eight years, the degree of microphthalmia had usually increased. The overall refraction decreased significantly in unilateral and bilateral cataract during the first four years of life. The mean values were higher in bilateral than in unilateral cataract at all ages. The mean decrease was 15 diopters in unilateral cataract (SD +/- 5.5 dpt), and 10 diopters in bilateral cataract (SD +/- 6 dpt). When correlating the age-matched differences in the ocular axial lengths at the time of surgery with the overall refractions after four to eight years, a good correlation was found in the unilateral cases (eight eyes), and a poor correlation in the bilateral cases (24 eyes). The data indicate that intraocular implants should not be used in bilateral cataract requiring surgery during the first year of life as long as there is no possibility to change their refraction while in place. In unilateral cases, a relatively accurate prediction appears possible in a small number of eight eyes. However, an additional important correction with glasses would be needed before reaching the final refraction resulting in a high degree of aniseiconia, and eliminating the chances for binocular vision that are small anyway. Furthermore, data from other authors would indicate that the change in refraction may be much more important than expected when using intraocular implants in unilateral congenital cataract requiring surgery during the first year of life.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- B Lorenz
- Department of Ophthalmology, University of Regensburg, Germany
| | | | | | | |
Collapse
|